|
US6143746A
(en)
*
|
1994-01-21 |
2000-11-07 |
Icos Corporation |
Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
|
|
GB9423910D0
(en)
|
1994-11-26 |
1995-01-11 |
Pfizer Ltd |
Therapeutic agents
|
|
US5958926A
(en)
*
|
1996-11-01 |
1999-09-28 |
Nitromed, Inc. |
Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
|
|
US6331543B1
(en)
|
1996-11-01 |
2001-12-18 |
Nitromed, Inc. |
Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
|
|
TR200001338T2
(tr)
|
1997-11-12 |
2000-08-21 |
Bayer Aktiengesellschaft |
2-Fenil-ikameli imidazotriazinonlar
|
|
AU2641199A
(en)
*
|
1998-02-27 |
1999-09-15 |
Kyowa Hakko Kogyo Co. Ltd. |
Remedies for erectile dysfunction
|
|
WO1999059584A1
(en)
*
|
1998-05-20 |
1999-11-25 |
Schering Corporation |
Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction
|
|
EP0967284A1
(en)
*
|
1998-05-28 |
1999-12-29 |
Pfizer Limited |
Phosphodiesterases
|
|
US6331571B1
(en)
|
1998-08-24 |
2001-12-18 |
Sepracor, Inc. |
Methods of treating and preventing attention deficit disorders
|
|
US6476078B2
(en)
|
1999-08-11 |
2002-11-05 |
Sepracor, Inc. |
Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
|
|
US6339106B1
(en)
|
1999-08-11 |
2002-01-15 |
Sepracor, Inc. |
Methods and compositions for the treatment and prevention of sexual dysfunction
|
|
US6974838B2
(en)
|
1998-08-24 |
2005-12-13 |
Sepracor Inc. |
Methods of treating or preventing pain using sibutramine metabolites
|
|
US6326379B1
(en)
|
1998-09-16 |
2001-12-04 |
Bristol-Myers Squibb Co. |
Fused pyridine inhibitors of cGMP phosphodiesterase
|
|
JP2000178204A
(ja)
*
|
1998-10-05 |
2000-06-27 |
Eisai Co Ltd |
ホスフォジエステラ―ゼ阻害剤を含有する口腔内速崩壊性錠剤
|
|
WO2000020033A1
(en)
*
|
1998-10-05 |
2000-04-13 |
Eisai Co., Ltd. |
Tablets immediately disintegrating in the oral cavity
|
|
JP2000191518A
(ja)
*
|
1998-10-19 |
2000-07-11 |
Eisai Co Ltd |
溶解性の改善された口腔内速崩壊性錠剤
|
|
UA67802C2
(uk)
*
|
1998-10-23 |
2004-07-15 |
Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. |
Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
|
|
WO2000053148A2
(en)
*
|
1999-03-08 |
2000-09-14 |
Merck & Co., Inc. |
Methods and compositions for treating erectile dysfunction
|
|
CA2365782A1
(en)
*
|
1999-04-30 |
2000-11-09 |
William E. Pullman |
Treatment of female arousal disorder
|
|
NO20002097L
(no)
*
|
1999-04-30 |
2001-10-26 |
Lilly Icos Llc |
Fremstillingsgjenstander
|
|
US6943166B1
(en)
*
|
1999-04-30 |
2005-09-13 |
Lilly Icos Llc. |
Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
|
|
US6451807B1
(en)
*
|
1999-04-30 |
2002-09-17 |
Lilly Icos, Llc. |
Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
|
|
NZ516616A
(en)
*
|
1999-08-03 |
2003-07-25 |
Lilly Icos Llc |
Beta-carboline pharmaceutical compositions
|
|
US6399826B1
(en)
|
1999-08-11 |
2002-06-04 |
Sepracor Inc. |
Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
|
|
GB9922124D0
(en)
*
|
1999-09-17 |
1999-11-17 |
Pfizer Ltd |
Phosphodiesterase enzymes
|
|
US6436944B1
(en)
*
|
1999-09-30 |
2002-08-20 |
Pfizer Inc. |
Combination effective for the treatment of impotence
|
|
EP1222190A1
(en)
|
1999-10-11 |
2002-07-17 |
Pfizer Limited |
5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dihydropyrazolo[4,3-d]pyrimidin-7-ones as phosphodiesterase inhibitors
|
|
UA72611C2
(uk)
*
|
2000-05-17 |
2005-03-15 |
Орто-Макнейл Фармацевтикал, Інк. |
Похідні заміщеного піролопіридинону, корисні як інгібітори фосфодіестерази
|
|
UA74826C2
(en)
|
2000-05-17 |
2006-02-15 |
Ortho Mcneil Pharm Inc |
?-carboline derivatives as phosphodiesterase inhibitors
|
|
EP1289989A2
(en)
*
|
2000-06-07 |
2003-03-12 |
Lilly Icos LLC |
Derivatives of 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
|
|
JP2004533402A
(ja)
*
|
2000-06-08 |
2004-11-04 |
リリー アイコス リミテッド ライアビリティ カンパニー |
Ｐｄｅｖインヒビターとしての四環系ジケトピペラジン化合物
|
|
CA2412594C
(en)
*
|
2000-06-23 |
2009-03-17 |
Lilly Icos Llc |
Pyrazino[1',2':1,6]pyrido[3-4-5] indole derivatives
|
|
ATE300543T1
(de)
*
|
2000-06-26 |
2005-08-15 |
Lilly Icos Llc |
Kondensierte pyrazindionderivate als pde5 inhibitore
|
|
WO2002010166A1
(en)
*
|
2000-08-02 |
2002-02-07 |
Lilly Icos Llc |
Fused heterocyclic derivatives as phosphodiesterase inhibitors
|
|
ATE552013T1
(de)
*
|
2000-09-06 |
2012-04-15 |
Mitsubishi Tanabe Pharma Corp |
Zubereitungen zur oralen anwendung
|
|
US6821978B2
(en)
*
|
2000-09-19 |
2004-11-23 |
Schering Corporation |
Xanthine phosphodiesterase V inhibitors
|
|
EP1325007B1
(en)
*
|
2000-10-02 |
2005-06-15 |
Lilly Icos LLC |
Hexahydropyrazino[1'2':1,6]-pyrido[3,4-b]indole-1,4-dione derivatives for the treatment of cardiovascular disorders and erectile disfunction
|
|
US6960587B2
(en)
|
2000-11-08 |
2005-11-01 |
Lilly Icos Llc |
Condensed pyrazindione derivatives as PDE inhibitors
|
|
EP1366760B1
(en)
*
|
2001-02-15 |
2010-06-30 |
Mitsubishi Tanabe Pharma Corporation |
Tablets quickly disintegrated in oral cavity
|
|
DE10118305A1
(de)
*
|
2001-04-12 |
2002-10-17 |
Bayer Ag |
Zusammensetzungen zur nasalen Applikation
|
|
WO2002083631A1
(en)
|
2001-04-13 |
2002-10-24 |
Sepracor Inc. |
Methods of preparing didesmethylsibutramine and other sibutramine derivatives
|
|
US7098209B2
(en)
*
|
2001-06-05 |
2006-08-29 |
Lilly Icos Llc |
Pyrazino [1'2':1,6 ] pyrido [3, 4-b] indole-1,4-dione derivatives
|
|
MXPA04001891A
(es)
*
|
2001-08-28 |
2004-06-15 |
Schering Corp |
Inhibidores policiclicos de guanina fosfodiesterasa v.
|
|
US20030087963A1
(en)
|
2001-09-13 |
2003-05-08 |
Senanayake Chris H. |
Methods of preparing and using 2-hydroxy derivatives of sibutramine and its metabolites
|
|
WO2003042216A1
(en)
*
|
2001-11-09 |
2003-05-22 |
Schering Corporation |
Polycyclic guanine derivative phosphodiesterase v inhibitors
|
|
CA2467269C
(en)
|
2001-11-14 |
2011-04-05 |
Weiqin Jiang |
Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors
|
|
ES2337887T3
(es)
*
|
2001-12-20 |
2010-04-30 |
Merck Serono Sa |
Derivados de pirrolidina en calidad de moduladores de prostaglandina.
|
|
US7893101B2
(en)
|
2002-03-20 |
2011-02-22 |
Celgene Corporation |
Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
|
|
US6962940B2
(en)
|
2002-03-20 |
2005-11-08 |
Celgene Corporation |
(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
|
|
US7276529B2
(en)
|
2002-03-20 |
2007-10-02 |
Celgene Corporation |
Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
|
|
US7208516B2
(en)
|
2002-03-20 |
2007-04-24 |
Celgene Corporation |
Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
|
|
DE10232113A1
(de)
|
2002-07-16 |
2004-01-29 |
Bayer Ag |
Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
|
|
WO2004011029A2
(en)
*
|
2002-07-26 |
2004-02-05 |
Adams Kenneth W |
Pharmaceutical compositions for penis enlargement
|
|
WO2005068464A2
(en)
*
|
2003-12-15 |
2005-07-28 |
Cadila Healthcare Limited |
Process for preparing tadalafil and its intermediates
|
|
NZ551356A
(en)
|
2004-05-11 |
2009-09-25 |
Emotional Brain Bv |
Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
|
|
US20060235005A1
(en)
*
|
2005-04-14 |
2006-10-19 |
Oak Labs, Corp. |
Use of phosphodiesterase 5 (PDE5) inhibitors in the treatment of schizophrenia
|
|
US8506934B2
(en)
|
2005-04-29 |
2013-08-13 |
Robert I. Henkin |
Methods for detection of biological substances
|
|
US20070010525A1
(en)
*
|
2005-06-27 |
2007-01-11 |
Meyer Jackson |
Method and compositions for modulating neuropeptide hormone secretion
|
|
JP2009502961A
(ja)
|
2005-07-29 |
2009-01-29 |
コンサート ファーマシューティカルズ インコーポレイテッド |
新規な医薬組成物
|
|
JP2009506069A
(ja)
|
2005-08-26 |
2009-02-12 |
ブレインセルス，インコーポレイティド |
ムスカリン性受容体調節による神経発生
|
|
EP2258359A3
(en)
|
2005-08-26 |
2011-04-06 |
Braincells, Inc. |
Neurogenesis by muscarinic receptor modulation with sabcomelin
|
|
WO2007033239A2
(en)
*
|
2005-09-13 |
2007-03-22 |
Elan Pharma International, Limited |
Nanoparticulate tadalafil formulations
|
|
US7985756B2
(en)
|
2005-10-21 |
2011-07-26 |
Braincells Inc. |
Modulation of neurogenesis by PDE inhibition
|
|
WO2007053596A1
(en)
|
2005-10-31 |
2007-05-10 |
Braincells, Inc. |
Gaba receptor mediated modulation of neurogenesis
|
|
ZA200804550B
(en)
|
2005-11-09 |
2009-08-26 |
Combinatorx Inc |
Methods, compositions, and kits for the treatment of medical conditions
|
|
EP1790343A1
(en)
|
2005-11-11 |
2007-05-30 |
Emotional Brain B.V. |
Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
|
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
|
US20080027072A1
(en)
*
|
2006-04-20 |
2008-01-31 |
Ampla Pharmaceuticals, Inc. |
Potentiation of MC4 receptor activity
|
|
WO2007134077A2
(en)
|
2006-05-09 |
2007-11-22 |
Braincells, Inc. |
5 ht receptor mediated neurogenesis
|
|
WO2007134136A2
(en)
|
2006-05-09 |
2007-11-22 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
|
RU2009103660A
(ru)
*
|
2006-07-07 |
2010-08-20 |
Тева Фармасьютикал Индастриес Лтд. (Il) |
Твердые фармацевтические композиции, включающие тадалафил и по меньшей мере один носитель
|
|
EP2068872A1
(en)
|
2006-09-08 |
2009-06-17 |
Braincells, Inc. |
Combinations containing a 4-acylaminopyridine derivative
|
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
|
EP1925307A1
(en)
|
2006-11-03 |
2008-05-28 |
Emotional Brain B.V. |
Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
|
|
WO2008095136A2
(en)
|
2007-01-31 |
2008-08-07 |
Henkin Robert I |
Methods for detection of biological substances
|
|
DK2114147T3
(da)
|
2007-02-12 |
2012-06-25 |
Dmi Biosciences Inc |
Reduktion af bivirkninger af tramadol
|
|
NZ579169A
(en)
*
|
2007-02-12 |
2012-05-25 |
Dmi Biosciences Inc |
Treatment of comorbid premature ejaculation and erectile dysfunction using tramadol and a phosphodiesterase (pde) inhibitor
|
|
WO2008134557A2
(en)
*
|
2007-04-25 |
2008-11-06 |
Teva Pharmaceutical Industries Ltd. |
Solid dosage forms
|
|
DE102007028869A1
(de)
*
|
2007-06-22 |
2008-12-24 |
Ratiopharm Gmbh |
Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
|
|
US20090181975A1
(en)
*
|
2008-01-15 |
2009-07-16 |
Forest Laboratories Holdings Limited |
Nebivolol in the treatment of sexual dysfunction
|
|
CN103479584A
(zh)
|
2008-05-02 |
2014-01-01 |
吉里德科学公司 |
固体载体颗粒在改善药物制剂加工性中的应用
|
|
US8580801B2
(en)
|
2008-07-23 |
2013-11-12 |
Robert I. Henkin |
Phosphodiesterase inhibitor treatment
|
|
AR073522A1
(es)
*
|
2008-09-30 |
2010-11-10 |
Biolab Sanus Farmaceutica Ltda |
Compuestos derivados de 2-(3-metilenodioxi) - benzoil indol
|
|
WO2010099217A1
(en)
|
2009-02-25 |
2010-09-02 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
|
JP6074142B2
(ja)
|
2009-02-26 |
2017-02-01 |
タール ファーマシューティカルズ，インコーポレイテッド |
医薬化合物の結晶化
|
|
DE102009033396A1
(de)
|
2009-07-16 |
2011-01-20 |
Ratiopharm Gmbh |
Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung
|
|
US10610528B2
(en)
*
|
2009-12-08 |
2020-04-07 |
Intelgenx Corp. |
Solid oral film dosage forms and methods for making same
|
|
US20110136815A1
(en)
|
2009-12-08 |
2011-06-09 |
Horst Zerbe |
Solid oral film dosage forms and methods for making same
|
|
UY33535A
(es)
*
|
2010-08-13 |
2011-12-01 |
Biolab Sanus Farmaceutuca Limitada |
Derivados de 6,7-dihidro-3h-oxazolo[3,4]pirazin-5,8-diona
|
|
RU2629116C2
(ru)
|
2011-10-14 |
2017-08-24 |
Эррэй Биофарма Инк. |
Полиморфы arry-380, селективного ингибитора erbb2, и фармацевтические составы, содержащие их
|
|
EP2804603A1
(en)
|
2012-01-10 |
2014-11-26 |
President and Fellows of Harvard College |
Beta-cell replication promoting compounds and methods of their use
|
|
MX357741B
(es)
*
|
2012-07-06 |
2018-07-23 |
Laboratorios Senosiain S A De C V Star |
Nuevas formas sólidas de inhibidores de fosfodiesterasa tipo 5.
|
|
WO2014055801A1
(en)
|
2012-10-05 |
2014-04-10 |
Henkin Robert I |
Phosphodiesterase inhibitors for treating taste and smell disorders
|
|
WO2015054132A1
(en)
*
|
2013-10-07 |
2015-04-16 |
Millennium Pharmaceuticals, Inc. |
Inhibitor of breast cancer resistance protein (bcrp)
|
|
US10598672B2
(en)
|
2014-02-18 |
2020-03-24 |
Cyrano Therapeutics, Inc. |
Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
|
|
JP6687550B2
(ja)
|
2014-06-23 |
2020-04-22 |
セルジーン コーポレイション |
肝疾患又は肝機能異常を治療するためのアプレミラスト
|
|
CN104086546B
(zh)
*
|
2014-07-14 |
2016-08-17 |
福建广生堂药业股份有限公司 |
他达拉非的药用酸盐及其制备方法
|
|
EP4620525A3
(en)
|
2016-12-14 |
2025-12-03 |
Respira Therapeutics, Inc. |
Methods and compositions for treatment of pulmonary hypertension and other lung disorders
|
|
LT3510997T
(lt)
|
2018-01-10 |
2021-01-11 |
Gap S.A. |
Minkšta želatinos kapsulė, apimanti tadalafilio suspensiją
|
|
WO2019241585A1
(en)
|
2018-06-14 |
2019-12-19 |
Astrazeneca Uk Limited |
Methods for treating erectile dysfunction with a cgmp-specific phosphodiesterase 5 inhibitor pharmaceutical composition
|
|
WO2021194893A1
(en)
|
2020-03-24 |
2021-09-30 |
Cyrano Therapeutics, Inc. |
Treatment of chemosensory dysfunction from a coronavirus infection
|
|
WO2021245192A1
(en)
|
2020-06-04 |
2021-12-09 |
Topadur Pharma Ag |
Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
|